Dan Suesskind Purchases 50,000 Shares of Nano-X Imaging (NASDAQ:NNOX) Stock

Nano-X Imaging Ltd. (NASDAQ:NNOX) Director Dan Suesskind bought 50,000 shares of the stock in a transaction on Monday, July 27th. The stock was bought at an average price of $0.93 per share, for a total transaction of $46,500.00. Following the completion of the purchase, the director directly owned 50,000 shares in the company, valued at approximately $46,500. The trade was a ? increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Nano-X Imaging Trading Down 0.9%

NASDAQ:NNOX opened at $0.88 on Wednesday. Nano-X Imaging Ltd. has a 12-month low of $0.73 and a 12-month high of $5.15. The stock’s 50 day simple moving average is $1.47 and its 200-day simple moving average is $2.08. The firm has a market cap of $61.08 million, a P/E ratio of -0.56 and a beta of 1.24.

Nano-X Imaging (NASDAQ:NNOX) last issued its quarterly earnings results on Thursday, June 25th. The company reported ($0.16) earnings per share for the quarter. Nano-X Imaging had a negative return on equity of 70.96% and a negative net margin of 716.44%.The company had revenue of $4.31 million for the quarter. Research analysts forecast that Nano-X Imaging Ltd. will post -0.6 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Nano-X Imaging in a research note on Wednesday, July 8th. Zacks Research upgraded shares of Nano-X Imaging from a “strong sell” rating to a “hold” rating in a research note on Monday, June 22nd. D. Boral Capital reissued a “buy” rating and set a $5.00 price target on shares of Nano-X Imaging in a report on Monday, April 20th. Finally, Alliance Global Partners downgraded shares of Nano-X Imaging from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $5.00 to $3.00 in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $4.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Kestra Advisory Services LLC purchased a new stake in shares of Nano-X Imaging during the 1st quarter worth $26,000. Independent Financial Group LLC purchased a new position in shares of Nano-X Imaging in the 1st quarter valued at about $26,000. Interchange Capital Partners LLC purchased a new position in shares of Nano-X Imaging in the 4th quarter valued at about $28,000. Aristides Capital LLC acquired a new stake in shares of Nano-X Imaging in the fourth quarter valued at about $30,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Nano-X Imaging in the first quarter valued at about $35,000. Hedge funds and other institutional investors own 21.49% of the company’s stock.

Trending Headlines about Nano-X Imaging

Here are the key news stories impacting Nano-X Imaging this week:

• Positive Sentiment: CEO Erez Meltzer purchased 36,000 NNOX shares at an average price of $0.93, investing approximately $33,480. The insider purchase may indicate management confidence in the company, although the relatively small transaction is unlikely to outweigh broader risks. SEC insider ownership filing
• Neutral Sentiment: Several law firms, including Rosen, Faruqi & Faruqi, Portnoy, Robbins, Pomerantz and others, are reminding investors about an August 11, 2026 deadline to seek lead-plaintiff status in a securities class action. These announcements are primarily investor solicitations, but their frequency increases attention surrounding Nano-X. Faruqi class action deadline notice
• Negative Sentiment: Pomerantz announced that a class action has been filed against Nano-X and certain officers. The lawsuit covers investors who purchased securities from March 31, 2025, through April 17, 2026, and adds potential litigation, reputational and legal-cost risks. The allegations have not been proven in court. Pomerantz class action announcement
• Negative Sentiment: The allegations focus on allegedly undisclosed cash burn and rising operating expenses preceding a $17.5 million impairment. Nano-X also continues to report losses, including quarterly revenue of $4.31 million and a loss of $0.16 per share, while analysts expect a full-year loss. SueWallSt class action notice

Nano-X Imaging Company Profile

Nano-X Imaging Ltd. is a medical technology company developing and commercializing a digital X-ray imaging platform designed to lower the cost and increase the accessibility of diagnostic imaging. Its flagship product, the Nanox.ARC, leverages a proprietary micro-electromechanical system (MEMS) based digital X-ray source and advanced image processing software to provide 2D and 3D imaging capabilities on a compact footprint. The system aims to streamline radiology workflows and facilitate point-of-care diagnostics in hospitals, clinics and outpatient settings.

The Nanox.ARC platform integrates a novel cold cathode X-ray source, which enables multiple emission points without the need for rotating anode tubes.